The latest DDF and portfolio news.

All News & Insights

Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001

May 30, 2024

Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme (…)

Logo of Amphista Therapeutics

Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium

May 23, 2024

First presentation of a novel mechanism of action for the degradation of BRD9 – completely differentiated from cereblon- or VHL-based (…)

Logo of Transposon

Transposon Receives US FDA Fast Track Designation for TPN-101 for Progressive Supranuclear Palsy

May 21, 2024

Designation Supports Accelerated Drug Development for PSP TPN-101 is the First PSP Treatment to Reduce NfL and IL-6 Levels, Key Biomarkers (…)

Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases

May 9, 2024

THN391 demonstrated effectiveness in protecting against vascular and neuronal degeneration – Therini Bio plans to initiate a Phase 1/2a trial (…)

Cerevance Achieves First Milestone in Research Collaboration with Merck

May 2, 2024

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) — Cerevance, a company focused on developing precision novel therapeutics for central nervous system (…)

Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline

April 25, 2024

Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others (…)

Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

April 24, 2024

Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a (…)

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

April 15, 2024

AVB-101 is an investigational gene therapy designed to deliver a functional copy of the GRN gene directly to the brain, (…)

2024 is shaping up to be another big year in the fight against dementia

March 26, 2024

As we approach the second quarter of 2024, the SV Health Investors Partners investing out of the Dementia Discovery Fund (…)

Cumulus Neuroscience Announces First Patient Enrolled in AccelADx Electroencephalogram (EEG) Study for Early Detection of Alzheimer’s Dementia

March 14, 2024

NIHR-Funded Study Represents the Largest of its Kind Conducted to Date in Alzheimer’s Dementia. Cumulus Neuroscience today announced the enrollment (…)

Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference

March 11, 2024

-Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic (…)

Logo of SUDO Biosciences

Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M

February 13, 2024

The funding will advance two precision TYK2 inhibitors into the clinic for multiple sclerosis, psoriasis and other severe autoimmune and (…)

Logo of Transposon

Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia

February 13, 2024

TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP (…)

Logo of Amphista Therapeutics

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

January 24, 2024

First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader Deep degradation of (…)

Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases

November 28, 2023

Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesis Refined focus (…)

Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck

November 21, 2023

Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck This transaction highlights DDF’s attractive strategy of investing in (…)

Logo of Transposon

Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for theTreatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases

November 14, 2023

24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a keybiomarker of neurodegeneration in tauopathies (…)

AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations

November 6, 2023

• AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain, enabling distribution to brain (…)

Cumulus Neuroscience to Present Data at CTAD 2023 Annual Meeting

October 18, 2023

Poster presentations scheduled for the 16th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting on Wednesday October 25th – Friday October 27th, (…)

AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations

October 10, 2023

• AVB-101 is an investigational gene therapy designed to halt disease progression by delivering a functional copy of the GRN (…)

AstronauTx closes a £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease

October 9, 2023

AstronauTx is a biotech company developing new treatments for neurodegenerative conditions based on amplifying the brain’s own physiological protective mechanisms (…)

UK biotech group raises £48mn for Alzheimer’s research

October 8, 2023

AstronauTx’s financing is step towards helping millions of people suffering from disease View the article  (…)

The Guardian: Pioneering a new era for dementia care

September 29, 2023

DDF Understanding Dementia (…)

Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023

August 28, 2023

Boston, MA – August 28, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision (…)

A born listener: CNS startup Violet hones in on cellular cross-talk

July 25, 2023

The identification of new targets in diseases of the central nervous system (CNS) such as Alzheimer’s and Parkinson’s – conditions (…)

DDF: Unleashing innovation, a new era for dementia

July 6, 2023

Dementia, the looming health crisis of our time, has long lacked effective treatments. But now, recent drug breakthroughs and the (…)

Renowned Neuroscientist Prof. Michael Heneka, M.D, Joins The Dementia Discovery Fund (DDF) as Scientific Advisor

June 28, 2023

Boston, MA (US) and London (UK) –June 28th 2023. The Dementia Discovery Fund (DDF), the world’s largest family of specialized venture capital (…)

On Building the Dementia Discovery Fund (DDF), the world’s premier venture capital fund focused on dementia

June 23, 2023

In conversation with Laurence Barker, a Partner with DDF Can you give me some background on the creation of DDF (…)

Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer’s Dementia Validation Trial

May 31, 2023

Oxford and Cambridge Among Sites Participating in CNS-101 Validation Study BELFAST, Northern Ireland and CAMBRIDGE, Mass., May 31, 2023 /PRNewswire/ (…)

Violet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Ventures (MGBV)

May 31, 2023

Round led by the DDF (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and founding investor (…)

First Steps to Treating Dementia May Lie in Related Diseases

May 19, 2023

AARP-backed research into ALS, Alzheimer’s could lead to dementia drugs View the article  (…)

Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease

May 15, 2023

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Therini Bio, Inc., a biotech company focused on developing fibrin-targeted therapies to treat inflammatory neurodegenerative and (…)

Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases

April 27, 2023

Funding from top-tier syndicate will be used to advance potential first-in-class investigational antibody THN391 into clinical trials. SOUTH SAN FRANCISCO, (…)

Nitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting

April 18, 2023

BRISBANE, Calif., April 18, 2023 (GLOBE NEWSWIRE) — Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build (…)

QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

April 6, 2023

First patient dosed in Canada in Phase 1 ANQUR study – the first-ever clinical trial to evaluate a therapy that (…)

ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies

March 9, 2023

QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA (…)

QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases

March 9, 2023

EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round Financing supports clinical activities for Company’s two lead programs (…)

AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology

February 23, 2023

• Subpial delivery technology has the potential to offer precise, efficient, and safer delivery of gene therapies for neurological diseases with (…)

Impact funds help fight dementia and antibiotic resistance

February 20, 2023

Some of the world’s biggest health challenges do not lend themselves to conventional investment “Dementia is a massive, massive swing (…)

Cerevance Expands Series B Financing with Additional $51 Million

February 13, 2023

Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase (…)

QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS

January 5, 2023

QRL-101 aims to reduce hyperexcitability-induced motor neuron degeneration CAMBRIDGE, Mass., January 5, 2023 – QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision (…)

Logo of Amphista Therapeutics

Dementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases

December 13, 2022

Cambridge, UK – December 13, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today (…)

QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

December 8, 2022

First ever study to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients expected to initiate in Canada in (…)

Nitrase Therapeutics Presented Data on Role of Novel Nitrases in Regulating Known and Important Cancer Targets at EORTC-NCI-AACR Symposium

October 31, 2022

Company discovered selective nitration and regulation of tumor-intrinsic and immuno-oncology targets by several of its proprietary nitrases BRISBANE, Calif., Oct. (…)

DDF recognizes that the latest lecanemab results represent major progress in the development of new treatments for Alzheimer’s disease.

September 29, 2022

Eisai and Biogen report positive results from lecanemab Phase 3 study in Alzheimer’s disease with a statistically significant slowdown in (…)

Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer

September 21, 2022

Tapping AliveCor Senior Executive, Cumulus Signals Progression To A Global Healthcare Company; Dr. Bhatti To Lead Expansion of AI-Based Digital (…)

AviadoBio selected by Fierce Biotech as a ‘Fierce 15’ 2022 winner

September 12, 2022

• Award reinforces AviadoBio’s position as one of the most promising early-stage biotech companies in the gene therapy industry London, (…)

Alchemab Therapeutics— Cracking the secrets of protective auto-immunity

September 12, 2022

Searching for protective antibodies in ‘resilient’ people may provide a new approach for discovering drug targets. View the article  (…)

Nitrase Therapeutics Appoints Arun Kashyap, Ph.D., to Lead its Recently Launched Oncology Programs as Senior Vice President of Oncology

September 7, 2022

BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) — Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build (…)

On heels of Parkinson’s readout, Cerevance enters Alzheimer’s discovery deal with Merck

August 9, 2022

Pharma pays $25M up front to use target discovery platform as privately-held Cerevance plots path forward for wholly-owned clinical program (…)

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

August 9, 2022

Cerevance to concurrently out-license one discovery-stage program Boston, MA – AUGUST 9, 2022 – Cerevance, a private, clinical-stage drug discovery and (…)

Nitrase Therapeutics Expands Leadership Team with Accomplished Drug Discovery and Development Executives

July 6, 2022

SAN FRANCISCO, July 06, 2022 (GLOBE NEWSWIRE) — Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its unique NITROME platform to (…)

QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board

June 21, 2022

Industry veteran brings proven track record in building successful businesses and leading high-performance teams across large pharmaceutical, biotech, and specialty (…)

Transine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development

May 31, 2022

Cambridge, UK, 31 May 2022: Transine Therapeutics (‘Transine’), a biotechnology company developing a novel class of therapeutic RNAs based on (…)

AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia

April 27, 2022

• FDA and EC decisions reinforce severity of unmet medical need with this rare, aggressive form of dementia • AviadoBio (…)

Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases

April 19, 2022

Craig Thompson Appointed Chief Executive Officer Founder Brad Margus Assumes Role of Executive Chairman of the Board Boston, MA – April (…)

Nitrase Therapeutics Receives New Grant from The Michael J. Fox Foundation for Parkinson’s Research

April 5, 2022

— Grant to fund exploration of potential new biomarker for Parkinson’s disease — BRISBANE, Calif., April 05, 2022 (GLOBE NEWSWIRE) (…)

Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism

March 31, 2022

Demonstrates the Power of Cerevance’s Deep Understanding of Specific Human Brain Cell Types Boston, MA – March 31, 2022 – Cerevance, (…)

Fast-track dementia to curb it like Covid

March 20, 2022

The coronavirus gave us a blueprint for tackling a health crisis: cut red tape and fund more research — but (…)

LoQus23: going upstream to slow Huntington’s disease

March 19, 2022

By targeting the DNA damage repair pathway, the U.K. biotech hopes to stop the formation of mutated HTT, not clean (…)

Nitrase Therapeutics Announces Major Discovery In Parkinson’s Disease Presented At The AD/PD International Conference

March 18, 2022

-Company Identifies Potential New Biomarker And Diagnostic For Parkinson’s Disease- SAN FRANCISCO, March 18, 2022 (GLOBE NEWSWIRE) — Nitrase Therapeutics, Inc. (…)

Caraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD

March 2, 2022

– Esteemed Harvard Medical School Professor Emeritus and HHMI Investigator, Dr. David Clapham, brings world class expertise on ciliary ion (…)

LoQus23 Therapeutics appoints Dr. Melanie Ivarsson, OBE, as Non-Executive Director

January 25, 2022

Dr. Ivarsson is currently Chief Development Officer at Moderna and led clinical trials of the company’s Covid-19 vaccineCambridge, UK – (…)

AviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform

December 1, 2021

Series A led by New Enterprise Associates (NEA) and co-led by Monograph Capital follows seeding by Advent Life Sciences, Dementia (…)

LoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund

November 23, 2021

– Company targets DNA mismatch repair pathways to slow neurodegeneration in Huntington’s Disease and other triplet repeat disorders – LoQus23’s (…)

Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics

November 2, 2021

–Founder Irene Griswold-Prenner, Ph.D., Focuses on Role as Chief Scientific Officer—San Francisco, CA – November 2, 2021 – Nitrase Therapeutics, Inc. (…)

Why Bill Gates is optimistic about the future of Alzheimer’s research

September 22, 2021

By loading the video, you agree to YouTube’s privacy policy.Learn more Load video Always unblock YouTube PGlmcmFtZSBsb2FkaW5nPSJsYXp5IiB3aWR0aD0iMTAwJSIgaGVpZ2h0PSI0ODAiIHNyYz0iaHR0cHM6Ly93d3cueW91dHViZS1ub2Nvb2tpZS5jb20vZW1iZWQvTi14WWhGb3FjeUkiIGZyYW1lYm9yZGVyPSIwIiBhbGxvdz0iYWNjZWxlcm9tZXRlcjsgYXV0b3BsYXk7IGVuY3J5cHRlZC1tZWRpYTsgZ3lyb3Njb3BlOyBwaWN0dXJlLWluLXBpY3R1cmUiIGFsbG93ZnVsbHNjcmVlbj0iIj48L2lmcmFtZT4= If we want (…)

QurAlis Announces Development Candidate for ALS Targeting STATHMIN-2

September 14, 2021

QRL-201 is a first-in-class molecule that rescues STATHMIN-2 loss of function in motor neuron disease models in the presence of (…)

Cumulus Neuroscience Appoints Dr Ruth McKernan CBE as Chair

September 14, 2021

BELFAST, Northern Ireland, Sept. 14, 2021 /PRNewswire/ — Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical (…)

Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO

July 5, 2021

Dr Thirkettle is a seasoned life sciences executive with deep experience and a proven track record in building successful novel (…)

GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases

July 2, 2021

GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, (…)

AARP celebrates DDF’s three-year anniversary of the final close of the Fund

June 24, 2021

Three years later, Dementia Discovery Fund now backs 18 companies seeking treatments View the article  (…)

Alchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer

June 22, 2021

Industry Veteran Brings Experience and Proven Track Record of Success Plans for Management Team Expansion and Global Reach Through Newly (…)

Kate Bingham is recognised in this year’s Queen’s Birthday Honours List

June 12, 2021

We are delighted to share the news that Kate Bingham, Managing Partner in the SV Biotech team, has been recognised in (…)

Right or wrong, the aducanumab decision could turbo-boost investor interest in neurodegeneration

June 11, 2021

Biocentury article (…)

The Dementia Discovery Fund’s Portfolio Company Caraway Therapeutics Establishes Collaboration with AbbVie to develop small molecule therapeutics targeting Parkinson’s disease and other neurodegenerative disorders

June 9, 2021

Boston, MA (US) and London (UK) – June 9, 2021. The Dementia Discovery Fund (DDF) is pleased to announce that Caraway Therapeutics, (…)

Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders

June 9, 2021

CAMBRIDGE, MA – June 9, 2021 – Caraway Therapeutics today announced an exclusive, collaboration and option agreement with AbbVie (NYSE: ABBV) to (…)

The Dementia Discovery Fund welcomes FDA’s approval of aducanumab for Alzheimer’s disease

June 7, 2021

Boston, MA (US) and London (UK) – June 7th, 2021. The Dementia Discovery Fund (DDF), the venture capital fund investing in, (…)

Transine Therapeutics Closes Extended Seed Funding of £9.1 million co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund to advance its novel class of therapeutic RNAs

June 2, 2021

New Company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression Cambridge, UK, 2nd June 2021: Transine Therapeutics (…)

QurAlis Boosts World-Class Leadership Team With Addition of Three New Members

May 26, 2021

Vikas Sharma, Ph.D., Shirley Lasch, and Tim O’Brien join team dedicated to developing new treatments for ALS and other genetically (…)

Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic

May 10, 2021

Strengthens investor syndicate with SV’s Impact Medicine Fund, MRL Ventures and Sanofi Ventures joining to accelerate development of disease-modifying drugs (…)

The Dementia Discovery Fund Appoints Luca Santarelli, M.D., a Proven Neuroscience Leader, as the New Chair of its Scientific Advisory Board

May 5, 2021

Boston, MA (US) and London (UK) – May 5th, 2021. The Dementia Discovery Fund (DDF), the venture capital fund investing in, and (…)

Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund

May 4, 2021

Proceeds to be used to advance next-generation integrated physiological and digital biomarker platform that provides clinical trial data and AI-powered (…)

Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics

April 15, 2021

Funding round led by RA Capital Management with Lightstone Ventures and DHVC follows a Seed round led by SV Health (…)

The Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio

April 7, 2021

World-recognized experts Dr. Lynne Hughes and Dr. James Summers appointed as Venture Partners Boston, MA (US) and London (UK) – April (…)

Amathus Therapeutics signs strategic collaboration with Merck to Develop Treatments for Neurodegenerative Diseases

March 17, 2021

Cambridge, MA, 17, March 2021 Amathus Therapeutics announced today a strategic collaboration with Merck, known as MSD outside the United (…)

Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease

March 16, 2021

Alchemab using unique approach to explore adaptive immunity – identifying naturally protective antibodies in ‘resilient patients’ to specific diseases Innovate (…)

QurAlis Continues to Expand Leadership Team with Two Key Hires

February 2, 2021

CAMBRIDGE, Mass., February 2, 2021— QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) (…)

Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics

January 6, 2021

Exclusive worldwide license and collaboration agreement to discover, develop and commercialize small molecule drug candidates against several RNA targets Partnership (…)

Caraway Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Further Investigate the Function of the Lysosomal Ion Channel TMEM175 and Gene Variants Linked to Parkinson’s Disease

November 18, 2020

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Caraway Therapeutics today announced that the Company has been awarded a second research grant from The Michael J. Fox (…)

Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study

November 16, 2020

Positive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia Boston, MA – (…)

Nitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson

November 12, 2020

Nitrome SAB composed of esteemed experts and key scientific thought leaders in neurobiology and drug development SAN FRANCISCO, Nov. 12, (…)

QurAlis named as one of Fierce Biotech’s 2020 Fierce 15

September 28, 2020

According to Fierce Biotech, what makes QurAlis fierce: There are currently four drugs approved by the U.S. FDA to treat ALS: (…)

Excellent news today from our portfolio company @Cerevance on the expansion of its Series B financing round, adding a further $20 million to the $45 million announced in April.

July 22, 2020

The additional proceeds will aid in the development of the company’s NETSseq platform which it is using to discover entirely (…)

QurAlis Announces Agreement to Strengthen ALS Pipeline

July 1, 2020

QurAlis to in-license lead excitotoxicity targeted ALS therapeutic candidates from LillyCambridge, MA, July 01, 2020 — QurAlis Corporation, a biotech company focused (…)

AstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer’s Disease

June 2, 2020

MANCHESTER, England, June 2, 2020 /PRNewswire/ — The therapeutics biotech AstronauTx announces a partnership with Concept Life Sciences, Contract Research (…)

QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)

May 13, 2020

Funding led by Polaris Partners, Mission BioCapital, INKEF Capital and the Dementia Discovery FundCAMBRIDGE, Mass.–(BUSINESS WIRE)–QurAlis Corporation, a biotech company (…)

Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases

April 23, 2020

Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related DiseasesThe (…)

Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer – an industry veteran who brings deep experience in drug development from leadership roles at Regeneron and Vertex

April 15, 2020

CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new (…)

Cerevance Closes $45 Million Series B Financing – proceeds to fund a diverse pipeline of therapeutics acting on novel targets for brain diseases

April 14, 2020

BOSTON, MA, April 14, 2020 (GLOBE NEWSWIRE) — Cerevance, a private drug discovery and development company focused on brain diseases, (…)

Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors

March 24, 2020

March 23, 2020 at 8:30 AM EDTSOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC) (…)

DDF notes the appointment of Christian Jung, PhD as Partner

September 9, 2019

SV Health Investors announces the appointment of Christian Jung, PhD as Partner in the Dementia Discovery Fund Former Principal at (…)

DDF notes AstronauTx secures £6.5 million Financing with Investment from DDF

August 12, 2019

Press Release: August 12, 2019 AstronauTx secures £6.5 million investment for new approach to dementia therapeutics First company created from (…)

DDF launches new research accelerator partnership with the UK DRI

October 23, 2018

Dementia Discovery Fund launches new research accelerator partnership with the UK Dementia Research Institute at inaugural Annual Forum for Dementia (…)

Bill Gates announces new investment in Alzheimer’s research to help launch Diagnostics Accelerator

July 19, 2018

The Dementia Discovery Fund welcomes Bill Gates’ second investment in Alzheimer’s research. Bill is joining Leonard Lauder, ADDF, the Dolby (…)

Dementia Discovery Fund Announces the Appointment of Angus Grant PhD as CEO

June 25, 2018

Dementia Discovery Fund announces the appointment of Angus Grant PhD as CEODr Grant from Celgene to join DDF in JulyDementia (…)

The Dementia Discovery Fund Raises $350 Million

June 25, 2018

Includes $60 million new investment from US AARPThe DDF is the world’s largest venture fund focused on a single disease (…)

DDF Announce Research Collaboration with Immuneering

June 19, 2018

The Dementia Discovery Fund and Immuneering announce a Research Collaboration to identify novel drug targets and drug candidates for Alzheimer’s (…)

DDF welcomes recent FDA guidance which opens new paths for Alzheimer’s treatments

February 20, 2018

13 February 2018The DDF welcomes new draft guidance from the FDA that endorses a new approach in Alzheimer’s Disease research (…)

JLABS – Meet With…Dementia Discovery Fund

January 2, 2018

Following last year’s meetings in New York and Cambridge, the DDF are again pleased to be presenting at upcoming Johnson (…)

DDF attracts investment from NFL Players Association

November 16, 2017

London, 16 November 2017 – The Dementia Discovery Fund (DDF) today announces an investment from the US National Football League Players (…)

DDF Invests in $20 Million in Series A Funding of Mitoconix Bio to Develop Neurodegenerative Disease Therapies

July 6, 2017

Ness Ziona, Israel June 27, 2017 – Mitoconix Bio Ltd., a biopharmaceutical company focused on therapies for neurological diseases, announced today (…)

Dementia Discovery Fund Annual Update

June 19, 2017

Dementia Discovery Fund Annual Update Nine investments made since launch, collaborations established with world-leading academic institutions, scientific strategy prioritised and (…)

Bicycle Therapeutics Closes £40 Million ($52 Million) in Series B Financing to Advance Clinical Pipeline

June 1, 2017

CAMBRIDGE, England & CAMBRIDGE, MA. (June 1, 2017) — Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based (…)

DDF to Invest $5 Million in Cerevance to Seek New Treatments for Dementia

May 3, 2017

Dementia Discovery Fund to Invest $5 Million in Cerevance to Seek New Treatments for Dementia London and Boston, 3 May (…)

Logo of autifony therapeutics

Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia

March 15, 2017

London, UK – 15th March 2017 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments (…)

DDF Acquires Small Molecule Library and Enters Strategic Partnership with Aptuit to Kickstart Dementia Drug Discovery Programmes

February 28, 2017

The Dementia Discovery Fund announces the acquisition of a >500,000 compound, CNS-biased small molecule library The DDF and Aptuit enter (…)

Launch of Dementia Discovery Fund New Fund Raises $100 Million to Deliver Novel Approaches to Treatment of Dementia

October 21, 2016

UK Department of Health, Alzheimer’s Research UK and major global pharmaceutical companies invest $100 Million Ground breaking collaboration to address (…)

DDF invests in Gen2 Neuroscience Ltd

June 3, 2016

Gen2 is a start-up drug discovery company seeking to develop drugs that target toxic tau species that cause pathology in (…)

SV appoints world-renowned Chief Scientific Officer to lead the new DDF investment team

January 25, 2016

Tetsuyuki Maruyama joins from Takeda Pharmaceutical Co. Ltd as CSO Laurence Barker from GSK also joins as Chief Business Officer (…)

DDF Makes First Investment In Alector LLC

January 7, 2016

First investment of Dementia Discovery Fund is in pioneering immuno-modulatory antibody discovery company, Alector LLCAlector LLC is developing antibody drugs (…)

Get in touch!

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you.
Send us an email